

Sze et al. Ethnicity and clinical outcomes in COVID-19

Ethnicity and clinical outcomes in COVID-19

A Systematic Review and Meta-analysis

Shirley Sze MD*¹
Daniel Pan* MRCP^{2,3}
Laura J Gray PhD*⁴
Clareece R Nevill MSc⁴
Christopher A Martin MRCP^{2,3}
Joshua Nazareth MRCP^{2,3}
Jatinder S Minhas MD¹
Pip Divall MSc⁵
Kamlesh Khunti PhD⁶
Keith R Abrams PhD⁴
Laura B Nellums PhD**⁷
Manish Pareek PhD**^{2,3}

*Joint first authors

**Joint senior authors

¹Department of Cardiovascular Sciences, University of Leicester, United Kingdom

²Department of Respiratory Sciences, University of Leicester, United Kingdom

³Department of Infection and HIV Medicine, University Hospitals Leicester NHS Trust, United Kingdom

⁴Department of Health Sciences, University of Leicester, United Kingdom

⁵University Hospitals of Leicester, Education Centre Library, Glenfield Hospital and Leicester Royal Infirmary, United Kingdom

⁶Diabetes Research Centre, University of Leicester, United Kingdom

⁷Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, United Kingdom

Correspondence to:

Dr Manish Pareek

Associate Clinical Professor in Infectious Diseases

Department of Respiratory Sciences

University of Leicester

Email: mp426@le.ac.uk

Abstract word count: 346

Manuscript word count: 2,986

Sze et al. Ethnicity and clinical outcomes in COVID-19

KEY POINTS

Question:

Is ethnicity associated with vulnerability to, and outcomes from, coronavirus disease 2019 (COVID-19)?

Findings:

In this systematic review and meta-analysis, rates of infection and outcomes from COVID-19 were compared between ethnic groups. Individuals from Black, Asian and Hispanic ethnicity were significantly more vulnerable to SARS-CoV-2 infection than those of White ethnicity. Black individuals were more likely to need intensive care unit (ICU) admission for COVID-19 than White individuals. Risk of mortality was similar across ethnicities among hospitalised patients, but increased among Asian and Mixed ethnic groups in the general population.

Meaning:

There is strong evidence for an increased risk of SARS-CoV-2 infection amongst ethnic minorities, and targeted public health policies are required to reduce this risk.

Sze et al. Ethnicity and clinical outcomes in COVID-19

ABSTRACT

Importance

The association of ethnicity with outcomes in patients with COVID-19 is unclear.

Objective

To determine whether the risk of SARS-CoV-2 infection, COVID-19 intensive care unit (ICU) admission and mortality are associated with ethnicity.

Data Sources

We searched all English language articles published 1st December 2019 - 30th June 2020 within MEDLINE, EMBASE, PROSPERO and the Cochrane library using indexing terms for COVID-19 and ethnicity, as well as manuscripts awaiting peer review on *MedRxiv* during the same period.

Study Selection

Included studies reported original clinical data, disaggregated by ethnicity, on patients with confirmed or suspected COVID-19. We excluded correspondence, area level, modelling and basic science articles. Two independent reviewers screened articles for inclusion. Of 926 identified articles, 35 were included in the meta-analyses.

Data Extraction and Synthesis

The review was conducted according to PRISMA guidelines. Reviewers independently extracted data using a piloted form on: (1) rates of infection, ICU admission and mortality by ethnicity; and (2) unadjusted and adjusted data comparing ethnic minority and White groups. Data were pooled using random effects models.

Main Outcomes and Measures

Outcomes were: (1) infection with SARS-CoV-2 confirmed on molecular testing; (2) ICU admission; and (3) mortality in COVID-19 confirmed and suspected cases.

Results

13,535,562 patients from 35 studies were included in the meta-analyses. Black, Asian and Hispanic individuals had a greater risk of infection compared to White individuals (Black: pooled adjusted RR: 2.06, 95% CI: 1.59-2.67; Asian: 1.35, 95%CI: 1.15-1.59; Hispanic: 1.77, 95% CI: 1.39-2.25). Black individuals were significantly more likely to be admitted to ICU than White individuals (pooled adjusted RR: 1.61, 95% CI: 1.02-2.55). Risk of mortality was similar across ethnicities among hospitalised patients, but increased among Asian and Mixed ethnic groups in the general population.

Conclusions

Black, Asian and Hispanic ethnic groups are at increased risk of SARS-CoV-2 infection. Black individuals may be more likely to require ICU admission for COVID-19. There may also be disparities in risk of death from COVID-19 at a population level. Our findings are of critical public health importance and should inform policy on minimising SARS-CoV-2 exposure in ethnic minority groups.

Sze et al. Ethnicity and clinical outcomes in COVID-19

Introduction

Over 25 million people have been infected with severe acute respiratory virus-2 (SARS-CoV-2) since December 2019.¹ Race and ethnicity has come under scrutiny as an important risk factor for infection, severe disease and death, with evidence that ethnic minorities may be at increased risk of COVID-19 morbidity and mortality.^{2,3}

Understanding the relationship between ethnicity and COVID-19 is an urgent research priority, in order to reduce the disproportionate burden of disease in these populations.^{4,5} Recently there has been an increase in the volume of literature, both published and in preprint servers, on the association of ethnicity with vulnerability to COVID-19 infection and clinical outcomes.⁶ A comprehensive synthesis of existing evidence examining the relationship between ethnicity and COVID-19 is urgently needed in order to inform clinical care and public health policy. We therefore conducted a systematic review and meta-analysis of both published and preprint research to study the association of ethnicity with COVID-19 infection and outcomes. Specifically, we aimed to identify ethnic differences in the risk of becoming infected with SARS-CoV-2 as well as subsequent intensive care admission and death.

Methods

We conducted the research according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and registered our review on PROSPERO (CRD42020180654).⁷

Sze et al. Ethnicity and clinical outcomes in COVID-19

Data sources and searches

An academic librarian (PD) developed the search strategies, and carried out a search of the databases MEDLINE, EMBASE, PROSPERO and the Cochrane Library, as shown in the Supplementary materials 1. We searched for any articles published in English from 1st December 2019 to 30th June 2020. We also reviewed any publications awaiting peer review on *MedRxiv* during the same period.

Eligibility criteria

We included studies with original clinical data on COVID-19 infection, intensive care admission, and mortality disaggregated by ethnicity. We excluded correspondence pieces, area level studies (reporting aggregated data rather than individual risk), and predictive modelling studies, or those that only included basic science or animal data or did not report population data (e.g. studies of infection breakouts). Retracted papers were also excluded. If studies assessed *race* and *ethnicity* separately, data were only extracted for mutually exclusive groups. Where multiple preprints of the same database have been published (for example, the Biobank database), the most recent version up to 30th June 2020 was used, with published peer-reviewed studies favoured over those in the preprint database. Studies which assessed two different cohorts in the same paper were included as two separate datasets in the analysis. We used rigorous methods to exclude duplicate publications by identifying centres and excluding studies using the same database.

Study selection

Sze et al. Ethnicity and clinical outcomes in COVID-19

Using a standardised piloted form, DP and SS independently screened titles, abstracts and full-text articles reporting potentially eligible studies. Disagreements were resolved by discussion or consultation with an adjudicator (MP) when necessary.

Data extraction

One reviewer (DP, SS, CAM, JN, JSM, LBN) independently extracted data from each article. Data extraction was duplicated for all papers by an independent researcher (CN). We stratified patients into the following ethnic groups based on the categorisations used in the included papers: White; Asian (including South Asian, Asian/Pacific-Islander and Chinese); Black; Hispanic; Native American; Mixed and Other. When the proportion of patients of each ethnicity was not presented in the text, we calculated the proportion from data in the manuscript.

The outcomes studied were:

- Infection with SARS-CoV-2
- Intensive Care Unit (ICU) admission
- Death

Patients with COVID-19 were defined as those who tested positive for SARS-CoV-2 by nasopharyngeal swab or had clinical symptoms and signs of COVID-19.

Data synthesis and analysis

We first synthesised prevalence of each outcome and unadjusted data by ethnicity. We excluded studies which did not record any events. Raw counts were used for the unadjusted data to calculate odds ratios (OR) and 95% confidence intervals (CI).

Sze et al. Ethnicity and clinical outcomes in COVID-19

We also synthesised data adjusted for key confounders. For risk of infection and ICU admission, we extracted adjusted risk ratios (RR). Adjusted OR were converted to adjusted RR using the conversion method as recommended by the Cochrane Handbook.⁸ For mortality, we extracted adjusted hazard ratios (HR) (95% CI) where possible, and assumed adjusted RR to approximate an adjusted HR.

Some studies presented multiple models with different sets of confounders. We included the model which most closely matched our *a priori* chosen confounders of age, sex, deprivation, obesity, and comorbidities. For both the adjusted and unadjusted comparisons, data were extracted for analyses which used White ethnicity as the reference group.

For ICU admission and mortality, we included studies which reported suspected or confirmed COVID-19 patients in their analyses. For mortality, we conducted a further analysis to include studies which looked at the risk of death from COVID-19 in the general population (i.e., those with and without COVID-19). Sensitivity analyses were also conducted excluding studies which did not include data for those still hospitalised at the end of the study, and studies which were of mixed populations (hospitalised and non-hospitalised patients).

For all outcomes and data types, we synthesised data (prevalence, unadjusted OR and adjusted RR/HR) using the DerSimonian and Laird random effects model.⁹ I^2 was used to assess heterogeneity. All meta-analyses were conducted using STATA version 16.1 (StataCorp, United States). *P* values <0.05 were considered to be statistically significant.

Quality of evidence

Sze et al. Ethnicity and clinical outcomes in COVID-19

Joanna Briggs Institute Critical Appraisal Tools were used to assess the quality of evidence for all studies relevant to each study design.¹⁰ Publication bias was assessed visually using funnel plots and formally with Egger's test for analyses including at least 10 studies.¹¹

Results

Study selection

282 articles were identified in the published literature between 1st December 2019 and 30th June 2020 as shown in Figure 1. An additional 644 articles were identified from *MedRxiv* within the same period, giving a total of 926 articles. 126 articles were excluded because they did not report on individuals with COVID-19; 57 were excluded due to no mention of ethnicity. Two papers were excluded due to retraction during the study period. Of the remaining 741 articles that were assessed for eligibility in full-text screening, 638 did not meet inclusion criteria (reasons for exclusion, Figure 1). A further 68 were excluded from the meta-analysis, including 62 studies which provided no data on our predefined outcomes, and six studies which used the same database as other included studies.

Study characteristics

A total of 13,535,562 patients from 35 papers¹²⁻⁴⁵ were included in the meta-analyses; 11,383,563 (84%) were White; 1,045,656 (8%) were Asian; 383,970 (2.8%) were Black, 32,066 (0.2%) were Hispanic, two were Native American, 349,038 (2.5%) were Mixed, and 341,267 (2.5%) were of Other ethnic group.

Detailed descriptions of the included studies are shown in Table 1. Most studies (n=28, 80%) were from the USA; the remaining six (17%) were from the UK. One study (3%)

Sze et al. Ethnicity and clinical outcomes in COVID-19

described two separate cohorts from the USA and the UK.¹⁹ One study (3%) was a case series; two (6%) were cross-sectional and the remaining (91%) were cohort studies. 20 (57%) reported on patients in hospital; three (9%) reported on patients in the community; 12 (34%) reported on both. As of 31st August 2020, half (n=18, 51%) of papers included were published.

The overall quality of published articles was higher than those in preprint; their average rating was 82% compared to 75% for preprint articles as shown in Table 1.

Risk of SARS-CoV-2 infection

Thirteen studies reported data on the risk of SARS-CoV-2 infection in those tested stratified by ethnicity, as shown in Table 2 and Supplementary materials 2. Pooled prevalence was highest in Mixed and Black groups. After adjusting for confounders, individuals of Black ethnicity had double the risk of SARS-CoV-2 compared to those of White ethnicity (pooled adjusted RR: 2.06, 95% CI: 1.59-2.67). There was also an increased risk of SARS-CoV-2 infection among those of Asian (pooled adjusted RR: 1.35, 95% CI: 1.15-1.59) and Hispanic ethnicity (pooled adjusted RR: 1.77, 95% CI: 1.39-2.25) compared to White ethnicity. Data for Mixed and Native American ethnicity were limited by small numbers of patients. Across all pooled analyses, there were high levels of heterogeneity.

ICU admission

Eleven studies reported data on the risk of ICU admission by ethnicity among COVID-19 patients, as shown in Table 3 and Supplementary materials 3. Pooled prevalence was highest in the Black group. Of these studies, four provided comparative estimates adjusted

Sze et al. Ethnicity and clinical outcomes in COVID-19

for confounders. From the adjusted pooled estimates, individuals of Black and Hispanic ethnicity were more likely to be admitted to ICU compared to those of White ethnicity. Although the effect estimates were similar (Black: pooled adjusted RR: 1.61, 95% CI: 1.02-2.55; Hispanic: pooled adjusted RR: 1.62, 95% CI 0.53-4.97), the association was only significant for those of Black ethnicity. Only unadjusted data were available for comparing the risk of ICU admission in those of Asian ethnicity to White ethnicity. This showed a trend towards increased risk of ICU admission (OR: 1.68, 95% CI: 0.95-2.99). One study presented data for Native American ethnicity (OR: 1.54, 95% CI: 0.08-34.79) and no studies for Mixed ethnicity.³⁵ Across all pooled analyses, there were high levels of heterogeneity.

Sensitivity analysis limited to hospitalised patients showed a higher prevalence of ICU admission for all ethnic groups compared to studies reporting hospitalised and community populations combined. Only one study presented adjusted RR for Black and Hispanic ethnic groups compared to White ethnicity for hospitalised patients, which showed no increased risk for ICU admission.¹⁷

Mortality

Twenty three studies provided data on the risk of mortality in patients with COVID-19, by ethnic groups, as shown in Table 4 and Supplementary materials 4. Pooled prevalence was highest in Asian and Mixed groups. Eleven studies provided adjusted comparative data; four provided adjusted data, but did not provide raw counts or unadjusted comparative data. An additional two studies provided data on the risk of mortality in COVID-19 patients in the general population, and were included in our sensitivity analysis.

From the adjusted pooled estimates of studies which looked at hospitalised patients with COVID-19, patients from ethnic minority backgrounds have a similar risk of death

Sze et al. Ethnicity and clinical outcomes in COVID-19

compared to those of White ethnicity. Sensitivity analysis which investigated the risk of death from COVID-19 in the general population showed that patients of Asian (pooled adjusted HR 1.46, 95% CI: 1.12-1.92) and Mixed (pooled adjusted HR: 1.47, 95% CI: 1.01-2.12) ethnicities have an increased risk of death compared to those of White ethnicity. Further sensitivity analyses excluding (1) studies not reporting mortality data on patients who were still hospitalised at the end of the study and (2) studies which were of mixed ethnic populations showed that patients from ethnic minority groups had a similar risk of death compared to those of White ethnicity.

Risk of bias across studies

For prevalence estimates of infection, there was clear asymmetry in funnel plots for Asian, Black and White ethnic groups (Egger's test $p=0.003$, $p=0.007$ and $p=0.001$ respectively, Supplementary materials 5). Studies with very low estimates of infection had very high precision, whereas studies with higher infection estimates had lower precision.

For prevalence estimates of ICU admission, there was some asymmetry in the funnel plot for White ethnic group (Egger's test $p=0.04$). For prevalence estimates of mortality, there was some asymmetry in the funnel plot for the Black ethnic group (Egger's test $p=0.006$). The asymmetry appears to be driven by small-study effects; the studies with low precision all had higher estimates of prevalence.

DISCUSSION

We present the first meta-analysis investigating the effect of ethnicity on COVID-19 clinical outcomes in both published and preprint research. We found that individuals from Asian,

Sze et al. Ethnicity and clinical outcomes in COVID-19

Black and Hispanic ethnic groups are more vulnerable to SARS-CoV-2 infection compared to those of White ethnicity. In addition, those of Black ethnicity are at higher risk of ICU admission compared to White. We found limited evidence suggesting that individuals from ethnic minority backgrounds are at increased risk of death.

Our findings suggest that the disproportionate impact of COVID-19 on ethnic minority communities is likely to be attributed to infection rather than high severity of disease. Elevated prevalence of SARS-CoV-2 in Black, Asian and Hispanic ethnic groups compared to those of White ethnicity may be attributed to a number of factors relating to increased transmission.^{46,47} This includes larger household sizes comprised of multiple generations, lower socioeconomic status and deprivation, which may increase the likelihood of living in urban or deprived areas, overcrowded households, or accommodation with shared facilities or communal areas.^{48,49} Individuals from ethnic minority backgrounds are more likely to be employed in keyworker roles, or less able to work from home, and as a result have continued to have contact with others through work or commuting.⁵⁰ In the Bureau of Labour Statistics Current Population Survey for the year 2019, Hawkins found that Black and Asian workers were more likely to be employed in occupations with both frequent exposures to infections and proximity to others.⁵¹ There is also evidence that ethnic minority groups experience disproportionate rates of COVID-19 morbidity and mortality in some of these occupational groups, for example among healthcare workers.⁵² Our findings that ethnic disparities exist in mortality rates at a population level may also be attributed to the higher risk of infection, as well as inequities in access to and quality of care, including language, cost, insurance, or structural discrimination.⁵³

Racism and structural discrimination may also contribute to an increased risk of transmission within ethnic minority communities.^{53,54} These processes are both complex

Sze et al. Ethnicity and clinical outcomes in COVID-19

and systemic, underpinned by unequal power relations and beliefs, and operating at individual, community, and organisational levels, resulting in stigmatisation, discrimination, and marginalisation of ethnic minorities.⁵⁵ Within the healthcare context, this contributes to inequities in the delivery of care, barriers to accessing care, loss of trust, and psychosocial stressors.^{56,57} During COVID-19, there is evidence that ethnic minorities and migrant groups have been less likely to implement public health measures, be tested, or seek care when experiencing symptoms due to such barriers and inequities in the availability and accessibility of care,⁵⁸ underscoring critical healthcare disparities.^{3,5}

We found that minority ethnic groups continue to be under-represented in research,⁵⁹ which is likely to be exacerbated by the same barriers that contribute to disparities in access to care and health outcomes.⁵³ Amongst our pooled cohort, only 16% of patients were from non-White ethnic backgrounds. In particular, pooled adjusted risk with regards to ICU admission and death were based on a small number of studies, limiting generalisability in these outcomes from our data.

Strengths and limitations

This is the first and only comprehensive synthesis of the existing evidence base, in which we provide a robust examination of both published peer-reviewed research and preprints reporting on COVID-19 outcomes in ethnic minority groups. Whilst the findings integrate the available data in this field, providing insight into disparities in COVID-19 outcomes in ethnic minorities in order to inform both policy and practice, our study had several limitations.

Sze et al. Ethnicity and clinical outcomes in COVID-19

Variations across papers in relation to populations, setting, treatment context, and reporting of ethnicity and outcomes, resulted in high heterogeneity. However, this does not preclude pooling of data and is consistent with other meta-analyses on infection in diverse populations.^{60,61} Instead, we explored heterogeneity through sensitivity analyses. The analyses provide an important visualisation of the data available, and highlight the heterogeneity across the research and need to improve data collection and analysis, including greater standardisation in adjusted analyses.

Several studies may have overlapping populations.⁶² For example, we found six studies from Mount Sinai investigating mortality from COVID-19; quite possibly from the same population.^{39,63–66} We have minimised this error by excluding studies which were clearly done on the same database, though we urge greater transparency in reporting for future research.

Finally, all studies included were from the UK and USA. Whilst both these countries have ethnically diverse populations, generalisability of our findings to other countries should be cautioned, and further research should be undertaken in other country contexts and diverse income-level settings.

Implications for future research

This research highlights the critical inconsistencies in the evidence base in categorisations of ethnicity and race, disaggregation of data, inclusion of confounders, and reporting standards. For example, only 6% (41/741) of potentially eligible articles we screened investigated ethnicity with relation to COVID-19 clinical outcomes. At least 8% (62/741) of studies may have generated outcome data, but did not provide this in their manuscript. Furthermore, of all 35 studies, only one separated Asian into South Asian,

Sze et al. Ethnicity and clinical outcomes in COVID-19

Pakistani and Chinese; an evidently heterogeneous group.^{27,67} This inhibits the ability to draw from the existing research to inform evidence-based policy and practice, and highlights the need to standardise data collection and reporting of ethnicity in research.

This research also illustrates the rapid generation of data during the pandemic, and the imperative to provide a comprehensive and transparent representation of the available evidence. As such, we included preprint articles, and did not exclude on the basis of quality. Though published peer-reviewed articles typically had higher quality scores, preprints meeting the inclusion criteria were generally of high quality (Supplementary figure 6). Ultimately, half of the studies included were preprints, underscoring the impetus to promote open access and transparency of data.

The research also highlighted the challenges in identifying emerging unpublished data in this quickly evolving evidence base. For example, two studies by Barron and colleagues and the ISARIC group^{68,69} were not included in *MedRxiv*. Study participants from the included OpenSAFELY publication would have significantly overlapped with Barron's whole-population study and findings from the ISARIC publication align with our conclusions.²⁸ However, this suggests the need to reimagine how preprint evidence can be disseminated and systematically examined in the post-pandemic context to enable more comprehensive and rapid synthesis of emerging findings.

Conclusions

We found strong evidence that patients of Black, Asian and Hispanic ethnicity are more vulnerable to SARS-CoV-2, compared to those of White ethnicity. As the COVID-19 pandemic continues to evolve, more studies should aim to present outcomes (hospitalisation, ICU admission and death) of patients with COVID-19 disaggregated by

Sze et al. Ethnicity and clinical outcomes in COVID-19

ethnicity, with data adjusted by key confounders. Policy-makers should strongly consider strategies to minimise exposure risk of SARS-CoV-2 in ethnic minority groups, by facilitating access to timely care, and targeting social determinants, structural racism, and occupational risk underlying inequities.

Sze et al. Ethnicity and clinical outcomes in COVID-19

References

1. Johns Hopkins University of Medicine Coronavirus Resource Center. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). <https://coronavirus.jhu.edu/map.html>. Accessed September 4, 2020.
2. Pan D, Sze S, Minhas JS, et al. The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. *EClinicalMedicine*. 2020;23:100404. doi:10.1016/j.eclinm.2020.100404
3. Williams D, Cooper L. COVID-19 and Health Equity - A New Kind of “Herd Immunity.” *JAMA*. 2020;323(24):2478-2480. doi:10.1001/jama.2020.8051
4. Pareek M, Bangash MN, Pareek N, et al. Ethnicity and COVID-19: an urgent public health research priority. *Lancet*. 2020;395(10234):1421-1422. doi:10.1016/S0140-6736(20)30922-3
5. Yancy CW. COVID-19 and African Americans. *JAMA - J Am Med Assoc*. 2020;323(19):1891-1892. doi:10.1001/jama.2020.6548
6. LITCOVID. LitCovid - Ethnicity search. <https://www.ncbi.nlm.nih.gov/research/coronavirus/docsum?text=Ethnicity>. Accessed September 4, 2020.
7. PROSPERO. The impact of ethnicity on clinical outcomes in COVID-19: a systematic review. https://www.crd.york.ac.uk/prospERO/display_record.php?RecordID=180654. Accessed September 4, 2020.
8. Higgins J, Thomas J. *The Cochrane Handbook for Systematic Reviews of Interventions*. 6th ed.; 2019.
9. Jackson D, Bowden J, Baker R. How does the DerSimonian and Laird procedure for

Sze et al. Ethnicity and clinical outcomes in COVID-19

- random effects meta-analysis compare with its more efficient but harder to compute counterparts? *J Stat Plan Inference*. 2010;140(4):961-970.
doi:10.1016/j.jspi.2009.09.017
10. Aromataris E, Munn Z. *JBI Manual for Evidence Synthesis*.
doi:<https://doi.org/10.46658/JBIMES-20-01>
 11. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *Br Med J*. 1997;315:629. doi:doi:
<https://doi.org/10.1136/bmj.315.7109.629>
 12. Ahmed SM, Shah RU, Bale M, et al. Comprehensive Testing Highlights Racial, Ethnic, and Age Disparities in the COVID-19 Outbreak. *medRxiv*. 2020:2020.05.05.20092031.
doi:10.1101/2020.05.05.20092031
 13. Argenzian MG, Bruc SL, Slate CL, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: Retrospective case series. *BMJ*. 2020;369(March). doi:10.1136/bmj.m1996
 14. Gold JAW, Wong KK, Szablewski CM, et al. Characteristics and clinical outcomes of adult patients hospitalized with COVID-19 — Georgia, March 2020. *Morb Mortal Wkly Rpt*. 2020;69(18):1-6.
 15. Gu T, Mack J, Salvatore M, et al. COVID-19 outcomes, risk factors and associations by race: a comprehensive analysis using electronic health records data in Michigan Medicine. *medRxiv*. 2020. doi:<https://doi.org/10.1101/2020.06.16.20133140>
 16. Khan A, Chatterjee A, Singh S. Comorbidities and Disparities in Outcomes of COVID-19 Among Black and White Patients. *medRxiv*. 2020.
doi:<https://doi.org/10.1101/2020.05.10.20090167>
 17. Kim L, Garg S, O'Halloran A, et al. Risk Factors for Intensive Care Unit Admission and

Sze et al. Ethnicity and clinical outcomes in COVID-19

- In-hospital Mortality among Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). *Clin Infect Dis*. 2020.
18. Levy TJ, Richardson S, Coppa K, et al. Development and Validation of a Survival Calculator for Hospitalized Patients with COVID-19. *medRxiv Prepr Serv Heal Sci*. 2020. doi:10.1101/2020.04.22.20075416
 19. Lo C-H, Nguyen LH, Drew DA, et al. Racial and ethnic determinants of Covid-19 risk. *medRxiv*. 2020:2020.06.18.20134742. doi:10.1101/2020.06.18.20134742
 20. de Lusignan S, Dorward J, Correa A, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. *Lancet Infect Dis*. 2020;20(9):1034-1042. doi:10.1016/S1473-3099(20)30371-6
 21. Marcello R, Dolle J, Grami S, et al. Characteristics and Outcomes of COVID-19 Patients in New York City's Public Hospital System. *medRxiv*. 2020. doi:<https://doi.org/10.1101/2020.05.29.20086645>
 22. Del Valle DM, Kim-Schulze S, Huang H-H, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med*. 2020;(3):1-8. doi:10.1038/s41591-020-1051-9
 23. Mendy A, Apewokin S, Wells AA, Morrow AL. Diverse Population of COVID-19 Patients. 2020:1-24.
 24. Auld SC, Caridi-Scheible M, Blum JM, et al. ICU and Ventilator Mortality Among Critically Ill Adults With Coronavirus Disease 2019. *Crit Care Med*. 2020;Publish Ah:1-6. doi:10.1097/ccm.0000000000004457
 25. Miles A, Webb TE, Mcloughlin BC, et al. Outcomes from COVID-19 across the range of

Sze et al. Ethnicity and clinical outcomes in COVID-19

frailty: excess mortality in fitter older people. *Eur Geriatr Med.* 2020;(0123456789).

doi:10.1007/s41999-020-00354-7

26. Narain S, Stefanov D, Chau A, et al. Comparative Survival Analysis of Immunomodulatory Therapy for COVID-19 “Cytokine Storm”: A Retrospective Observational Cohort Study. *medRxiv.* 2020.
doi:<https://doi.org/10.1101/2020.06.16.20126714>
27. Niedzwiedz CL, O'Donnell CA, Jani BD, et al. Ethnic and socioeconomic differences in SARS-CoV-2 infection: Prospective cohort study using UK Biobank. *BMC Med.* 2020;18(1):1-14. doi:10.1186/s12916-020-01640-8
28. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature.* 2020;584(7821):430-436.
doi:10.1038/s41586-020-2521-4
29. Petrak R, Skorodin N, Hise N, et al. Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARSCoV-2. *medRxiv.* 2020.
doi:<https://doi.org/10.1101/2020.06.05.20122622>
30. Price-Haywood EG, Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and mortality among black patients and white patients with Covid-19. *N Engl J Med.* 2020;382(26):2534-2543. doi:10.1056/NEJMsa2011686
31. Ramaswamy M, Mannam P, Comer R, Sinclair E, McQuaid DB, Schmidt ML. Off-Label Real World Experience Using Tocilizumab for Patients Hospitalized with COVID-19 Disease in a Regional Community Health System: A Case-Control Study. *medRxiv.* 2020:2020.05.14.20099234. doi:10.1101/2020.05.14.20099234
32. Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment with Hydroxychloroquine or Azithromycin with In-Hospital Mortality in Patients with

Sze et al. Ethnicity and clinical outcomes in COVID-19

- COVID-19 in New York State. *JAMA - J Am Med Assoc.* 2020;323(24):2493-2502.
doi:10.1001/jama.2020.8630
33. Sapey E, Gallier S, Mainey C, et al. Ethnicity and risk of death in patients hospitalised for COVID-19 infection in the UK: an observational cohort study in an urban catchment area. *medRxiv.* 2020. doi:<https://doi.org/10.1101/2020.05.05.20092296>
34. Somers E, Eschenauer G, Troost J, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. *Clin Infect Dis.* doi:10.1093/cid/ciaa839
35. Azar K, Shen Z, Romanelli R, et al. Disparities in Outcomes among COVID-19 patients in a large health care system in California. *Health Aff.* 2020;39(7).
doi:<https://doi.org/10.1377/hlthaff.2020.00598>
36. Vahidy FS, Nicolas JC, Meeks JR, et al. Racial and ethnic disparities in SARS-CoV-2 pandemic: analysis of a COVID-19 observational registry for a diverse US metropolitan population. *BMJ Open.* 2020;10(8):e039849. doi:10.1136/bmjopen-2020-039849
37. Velu P, Craney A, Ruggiero P, et al. Rapid implementation of SARS-CoV-2 emergency use authorization RT-PCR 2 testing and experience at an academic medical institution. *medRxiv.* 2020. doi:<https://doi.org/10.1101/2020.06.05.20109637>
38. Wang A-L, Zhong X, Hurd Y. Comorbidity and Sociodemographic determinants in COVID-19 Mortality in an US Urban Healthcare System. *medRxiv.* 2020:2020.06.11.20128926. doi:10.1101/2020.06.11.20128926
39. Wang Z, Zheutlin AB, Kao Y-H, et al. Analysis of hospitalized COVID-19 patients in the Mount Sinai Health System using electronic medical records (EMR) reveals important prognostic factors for improved clinical outcomes. *medRxiv.* 2020:2020.04.28.20075788. doi:10.1101/2020.04.28.20075788
40. Brill SE, Jarvis HC, Ozcan E, et al. COVID-19: A retrospective cohort study with focus

Sze et al. Ethnicity and clinical outcomes in COVID-19

on the over-80s and hospital-onset disease. *BMC Med.* 2020;18(1):1-9.

doi:10.1186/s12916-020-01665-z

41. Caraballo C, McCullough M, Fuery M, et al. COVID-19 Infections and Outcomes in a Live Registry of Heart Failure Patients Across an Integrated Health Care System. *medRxiv.* 2020:1-23.
<https://www.medrxiv.org/content/10.1101/2020.04.27.20082016v1.full.pdf>.
42. Rajter JC, Sherman M, Fatteh N, Voge F, Sacks J, Rajter J-J. ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is associated with lower mortality in hospitalized patients with COVID19. *medRxiv.* 2020:19.
doi:<https://doi.org/10.1101/2020.06.06.20124461>
43. Ebinge JE, Achamallah N, Ji H, et al. Pre-existing traits associated with Covid-19 illness severity. *PLoS One.* 2020;15(7 July):1-16. doi:10.1371/journal.pone.0236240
44. Ellington S, Strid P, Tong V, et al. Characteristics of Women of Reproductive Age with Laboratory Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-June 7, 2020. *Centers Dis Control Prev Morb Mortal Wkly Report, June 26 2020.* 2020;69(25).
45. Garibaldi BT, Fiksel J, Muschelli J, et al. Patient trajectories and risk factors for severe outcomes among persons hospitalized for COVID-19 in the Maryland/DC region. *medRxiv.* 2020. doi:<https://doi.org/10.1101/2020.05.24.20111864>
46. Rubin R. Health agencies update: Household Composition May Explain COVID-19 Racial/Ethnic Disparities. *J Am Med Assoc.* 2020;324(8):732.
doi:10.1001/jama.2020.14375
47. Martin CA, Jenkins DR, Minhas JS, et al. Socio-demographic heterogeneity in the prevalence of COVID-19 during lockdown is associated with ethnicity and household

Sze et al. Ethnicity and clinical outcomes in COVID-19

- size: Results from an observational cohort study. *EClinicalMedicine*. 2020;25:100466.
doi:10.1016/j.eclinm.2020.100466
48. Jing Q-L, Liu M-J, Zhang Z-B, et al. Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study. *Lancet Infect Dis*. 2020;3099(20):1-10. doi:10.1016/s1473-3099(20)30471-0
49. Iacobucci G. Covid-19: Deprived areas have the highest death rates in England and Wales. *BMJ*. 2020;369(May):m1810. doi:10.1136/bmj.m1810
50. Office for National Statistics United Kingdom Government. Coronavirus (COVID-19) related deaths by occupation, England and Wales: deaths registered up to and including 20 April 2020. 2020.
<https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/causesofdeath/bulletins/coronaviruscovid19relateddeathsbyoccupationenglandandwales/deathsregistereduptoandincluding20april2020>. Accessed September 4, 2020.
51. Hawkins D. Differential occupational risk for COVID-19 and other infection exposure according to race and ethnicity. *Am J Ind Med*. 2020;63(9):817-820.
doi:10.1002/ajim.23145
52. Nguyen LH, Drew DA, Graham MS, et al. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. *Lancet Public Heal*. 2020. doi:10.1016/s2468-2667(20)30164-x
53. Hooper M, Napoles A, Perez-Stable E. COVID-19 and Racial/Ethnic Disparities. *JAMA*. 2020;323(24):2466-2467. doi:doi:10.1001/jama.2020.8598
54. Egede LE, Walker RJ. Structural Racism, Social Risk Factors and COVID-19 - A Dangerous Convergence for Black Americans. *N Engl J Med*. 2020.
doi:10.1056/NEJMp2023616

Sze et al. Ethnicity and clinical outcomes in COVID-19

55. Szczepura A. Access to health care for ethnic minority populations. *Postgrad Med J*. 2005;81(953):141-147. doi:10.1136/pgmj.2004.026237
56. Doctors of the World. A Rapid Needs Assessment of Excluded People in England During the 2020 COVID-19 Pandemic. 2020;(May).
57. Caldwell JG, Price E V., Schroeter AL, Fletcher GF. Aortic regurgitation in the tuskegee study of untreated syphilis. *J Chronic Dis*. 1973;26(3):187-194. doi:10.1016/0021-9681(73)90089-1
58. Devakumar D, Shannon G, Bhopal SS, Abubakar I. Racism and discrimination in COVID-19 responses. *Lancet*. 2020;395(10231):1194. doi:10.1016/S0140-6736(20)30792-3
59. Chastain D, Osaë S, Henao-Martinez A, Franco-Paredes C, Chastain J, Young H. Racial Disproportionality in Covid Clinical Trials. *N Engl J Med*. 2020;383(e59). doi:10.1056/NEJMp2021971
60. Nellums LB, Thompson H, Holmes A, et al. Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis. *Lancet Infect Dis*. 2018;18(7):796-811. doi:10.1016/S1473-3099(18)30219-6
61. Aldridge RW, Nellums LB, Bartlett S, et al. Global patterns of mortality in international migrants: a systematic review and meta-analysis. *Lancet*. 2018;392(10164):2553-2566. doi:10.1016/S0140-6736(18)32781-8
62. Senn SJ. Overstating the evidence - Double counting in meta-analysis and related problems. *BMC Med Res Methodol*. 2009;9(1):1-7. doi:10.1186/1471-2288-9-10
63. Sigel K, Swartz T, Golden E, et al. Coronavirus 2019 and People Living With Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City. *Clin Infect Dis*. 2020;10029(Xx):1-6. doi:10.1093/cid/ciaa880

Sze et al. Ethnicity and clinical outcomes in COVID-19

64. Malle L, Gao C, Bouvier N, Percha B, Bogunovic D. COVID-19 Hospitalization is More Frequent and Severe in Down Syndrome and Affects Patients a Decade Younger. *medRxiv*. 2020. doi:<https://doi.org/10.1101/2020.05.26.20112748>
65. Wang B, Van Oekelen O, Mouhieddine TH, et al. A tertiary center experience of multiple myeloma patients with COVID-19: Lessons learned and the path forward. *J Hematol Oncol*. 2020;13(1):1-12. doi:10.1186/s13045-020-00934-x
66. Paranjpe I, Russak AJ, Freitas JK De, et al. Clinical Characteristics of Hospitalized Covid-19 Patients in New York City. *medRxiv*. 2020:1-20. doi:<https://doi.org/10.1101/2020.04.19.20062117>
67. Treweek S, Forouhi NG, Narayan K MV, Khunti K. COVID-19 and ethnicity: who will research results apply to? *Lancet*. 2020;395(10242):1955-1957. doi:10.1016/S0140-6736(20)31380-5
68. Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. *Lancet Diabetes Endocrinol*. 2020;8587(20). doi:10.1016/s2213-8587(20)30272-2
69. Harrison EM, Docherty AB, Barr B, et al. *Ethnicity and Outcomes from COVID-19: The ISARIC CCP-UK Prospective Observational Cohort Study of Hospitalised Patients.*; 2020. doi:10.2139/ssrn.3618215

Sze et al. Ethnicity and clinical outcomes in COVID-19

Funding

DP, SS and CAM are supported by the NIHR. JSM is funded by an NIHR Clinical Lectureship in Older People and Complex Health Needs. CAM is supported by an NIHR academic clinical fellowship. CRN works for the Complex Reviews Support Unit which is funded by the NIHR (project number 14/178/29). KRA is supported by Health Data Research (HDR) UK, the UK National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC EM), and as a NIHR Senior Investigator Emeritus (NF-SI-0512-10159). LBN receives funding from the Academy of Medical Sciences (SBF005\1047), the Medical Research Council/Economic and Social Research Council/Arts and Humanities Research Council (MR/T046732/1), and UKRI/MRC (MR/V027549/1). LJG receives funding from UK National Institute for Health Research (NIHR) and UKRI. KK, KM, MP and LG are supported by the National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC EM). KK and MP are supported by the NIHR Leicester Biomedical Research Centre (BRC). MP and KRA are members of the Health Data Research (HDR) UK COVID-19 Taskforce. MP is supported by a NIHR Development and Skills Enhancement Award and UKRI/MRC/NIHR (MR/V027549/1). KK and MP are supported by NIHR Leicester Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the NIHR, NHS or the Department of Health and Social Care.

Disclosures

KRA has served as a paid consultant, providing unrelated methodological advice, to; Abbvie, Amaris, Allergan, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Meyers Squibb, Creativ-Ceutical, GSK, ICON/Oxford Outcomes, Ipsen, Janssen, Eli Lilly, Merck, NICE, Novartis, NovoNordisk, Pfizer, PRMA, Roche and Takeda, and has received research funding from Association of the British Pharmaceutical Industry (ABPI), European Federation of Pharmaceutical Industries & Associations (EFPIA), Pfizer, Sanofi and Swiss Precision Diagnostics. He is a Partner and Director of Visible Analytics Limited, a healthcare consultancy company. KK has received honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi, Takeda, Servier and Pfizer, and research support from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi and Pfizer. KK is Director for the University of Leicester Centre for BME Health, Trustee of the South Asian Health Foundation, national NIHR ARC lead for Ethnicity and Diversity, Chair of the SAGE subgroup on Ethnicity and COVID and a member of Independent SAGE. MP reports grants and personal fees from Gilead Sciences and personal fees from QIAGEN, outside the submitted work.

Sze et al. Ethnicity and clinical outcomes in COVID-19

Figure and Table legends

Figure 1: PRISMA flowchart of study

Table 1: Characteristics of the 35 included studies. Rows in bold are articles which have been published in peer reviewed journals

Table 2: Data syntheses for risk of infectivity of SARS-CoV-2 by differing ethnic groups

Table 3: Data syntheses for risk of ICU admission amongst different ethnic groups

Table 4: Data syntheses for risk of mortality by different ethnic groups

Supplementary materials

Supplementary material 1: Search strategy for meta-analysis

Supplementary material 2a: Forrest plot of pooled prevalence of SARS-CoV-2 by ethnicity

Supplementary material 2b: Forrest plot of pooled unadjusted risk of SARS-CoV-2 infection by ethnicity (Reference group: White)

Supplementary material 2c: Forrest plot of pooled adjusted risk of SARS-CoV-2 infection by ethnicity (Reference group: White)

Supplementary material 3a: Forrest plot of pooled prevalence of ICU admission for COVID-19 by ethnicity (Reference group: White)

Supplementary material 3b: Forrest plot of pooled unadjusted risk of ICU admission for COVID-19 by ethnicity (Reference group: White)

Supplementary material 3c: Forrest plot of pooled adjusted risk of ICU admission for COVID-19 by ethnicity (Reference group: White)

Supplementary material 4a: Forrest plot of pooled prevalence of death from COVID-19 by ethnicity (Reference group: White)

Supplementary material 4b: Forrest plot of pooled unadjusted risk of death from COVID-19

Sze et al. Ethnicity and clinical outcomes in COVID-19

by ethnicity (Reference group: White)

Supplementary material 4c: Forrest plot of adjusted risk of death from COVID-19 in Black individuals (Reference group: White)

Supplementary material 4d: Forrest plot of adjusted risk of death from COVID-19 in Asian individuals (Reference group: White)

Supplementary material 4e: Forrest plot of adjusted risk of death from COVID-19 in Hispanic individuals (Reference group: White)

Supplementary material 4f: Forrest plot of adjusted risk of death from COVID-19 in Mixed individuals (Reference group: White)

Supplementary material 5: Funnel plots and Egger's test for the risk of infection, admission to ICU and death

Supplementary table 6: Quality rating score for each study.

Table 1. Characteristics of included studies

Study	Country	Study design	Setting	Published period	Population	White	Asian	Black	Hispanic	Mixed	Native American	Other
Ahmed ⁱ	USA	Cohort	Hospital/Community	May 2020	All patients within Uhealth, Utah Health system	489	30	31	402	0	6	271
Argenziano ⁱⁱ	USA	Case series	Hospital	May 2020	All patients who received care at a New York Hospital	144	19	181	248	0	0	408
Auld ⁱⁱⁱ	USA	Cohort	Hospital	May 2020	Critically ill adults across one academic health care system	39	7	153	0	0	0	18
Azar ^{iv}	USA	Cohort	Hospital/Community	May 2020	All patients at Sutter Health healthcare system in Northern California	428	124	61	271	0	2	166
Bril ^v	UK	Cohort	Hospital	June 2020	Retrospective cohort study of first 450 patients admitted to one hospital with confirmed COVID-19	265	51	33	0	0	0	77
Caraballo ^{vi}	USA	Cohort	Hospital	May 2020	Yale Heart Failure Registry (NCT04237701) includes 26,703 patients with heart failure across a 6-	119	0	62	0	0	0	0

Rajiter ^{vii}	USA	Cohort	Hospital	June 2020	hospital integrated health care system in Connecticut was queried on April 16th, 2020 for all patients.	76	0	153	33	0	0	13
Ebinger ^{viii}	USA	Cohort	Hospital	July 2020	All patients who presented to a Healthcare system in LA	283	35	58	0	0	0	66
Ellington ^{ix}	USA	Cohort	Community	June 2020	CDC reports of women of reproductive age	18817	2123	16381	25442	0	0	2620
Garibaldi ^x	USA	Cohort	Hospital	May 2020	Five hospitals in the Johns Hopkins Medicine system	266	48	333	134	0	0	43
Gold ^{xi}	USA	Cohort	Hospital	May 2020	Hospitalised adults in Georgia (primarily metropolitan Atlanta)	32	8	247	10	0	0	0
Gu ^{xii}	USA	Cohort	Community	June 2020	Participants tested in Michigan	461	0	418	0	0	0	108
Khan ^{xiii}	USA	Cohort	Community and Hospital	May 2020	Patients 10 years or older between January 20, 2020 and April 21, 2020	3435	0	2621	0	0	0	0

Kim ^{xiv}	USA	Cohort	Hospital	May 2020	154 acute care hospitals in 74 counties in 13 states, hospitalised patients	1178	0	755	306	0	0	251
Levy ^{xv}	USA	Cohort	Hospital	June 2020	Retrospective analysis for development, internal validation, prospective internal validation and external validation of a model to predict survival	4250	952	2336	0	0	0	3048
Lo ^{xvi}	UK	Cohort	Community	June 2020	Participants in the USA and UK	8335	638	121	15	0	0	226
Lo ^{xvii}	USA	Cohort	Community	June 2020	Participants in the USA and UK	498	41	65	89	0	0	23
Lusignan ^{xviii}	UK	Cross-section	Community and Hospital	May 2020	Patients from primary care medical records in the oxford RCGP research and surveillance centre network between Jan 28 and April 4 2020	388	47	36	0	20	0	0
Marcello ^{xix}	USA	Cohort	Hospital	June 2020	Single centre study of hospitalised patients	534	374	1950	2102	0	0	1288
Marie Del	USA	Cohort	Hospital	August	Hospitalised	277	73	278	577	0	0	63

Vale^{xx}				2020	patients at the Mount Sinai Health System in New York							
Mendy^{xxi}	USA	Cohort	Community and Hospital	June 2020	Patients diagnosed at the University of Cincinnati health system	201	0	176	224	0	0	88
Miles^{xxii}	UK	Cohort	Hospital	July 2020	Patients admitted to one hospital in London, aged 70+	138	16	16	0	19	0	28
Narain^{xxiii}	USA	Cohort	Hospital	June 2020	Hospitalised patients in the Northwell health system	1042	410	576	0	177	0	893
Niedzwiedz^{xxiv}	UK	Cohort	Community and Hospital	May 2020	UK Biobank analysis	371460	8456	6395	0	2356	0	3429
Williamson^{xxv}	UK	Cohort	Community	July 2020	NHS primary healthcare data; CPNS inpatient hospital death notifications; ONS death data	10962999	1030980	343437	0	171929	0	323813
Petrak^{xxvi}	USA	Cohort	Hospital	June 2020	To evaluate the clinical outcomes of patients treated with Tocilizumab	56	5	43	32	0	0	9
Price-haywood^{xxvii}	USA	Cohort	Community and Hospital	May 2020	Patients seen within Ochsner Health in Louisiana	1030	0	2451	0	0	0	0

Ramaswamy ^{xxviii}	USA	Cohort	Hospital	May 2020	Cone Health's enterprise analytics data	38	0	40	0	0	0	8
Rentsch ^{xxix}	USA	Cohort	Community and Hospital	April 2020	Data from the national corporate data warehouse	161	0	350	48	0	0	26
Rosenberg ^{xxx}	USA	Cohort	Hospital	May 2020	A random sample of all admitted patients in 25 hospitals representing 88% of patients with COVID-19 in the New York region between March 15 and 28 2020	321	0	371	364	0	0	243
Sapey ^{xxxi}	UK	Cohort	Hospital	May 2020	Hospitalised patients admitted to University Hospitals Birmingham	1540	410	134	0	18	0	67
Somers ^{xxxii}	USA	Cohort	Hospital	July 2020	To assess the effectiveness and safety of Tocilizumab in a single centre cohort of patients requiring mechanical ventilation	41	0	81	0	0	0	32
Vahidy ^{xxxiii}	USA	Cross-sectional	Community and	July 2020	COVID-19 surveillance and outcomes registry	390	78	246	0	0	0	40

			Hospital		(CURATOR) at the Houston Methodist Hospital system							
Velu ^{xxxiv}	USA	Cohort	Community and Hospital	June 2020	Clinical validation and implementation of lab-developed real time RT-PCR	156	28	66	0	0	0	95
Wang ^{xxxv}	USA	Cohort	Community and Hospital	June 2020	Patients with COVID-19 in New York City	2044	385	1787	0	0	0	2860
Wang ^{xxxvi}	USA	Cohort	Hospital	May 2020	Patient-level data were extracted from electronic medical records for 28,336 patients tested for SARS-CoV-2 at the Mount Sinai Health System from 2/24/ to 4/15/2020, including 6,158 laboratory-confirmed cases.	1642	318	1528	1769	0	0	947

ⁱ Ahmed SM, Sha RU, Bale M *et al.* Comprehensive testing highlights racial, ethnic and age disparities in the Covid-19 outbreak. *MedRxiv* 2020. <https://www.medrxiv.org/content/10.1101/2020.05.05.20092031v1>

ⁱⁱ Argenziano MG, Bruce SL, Slater CL *et al.* Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. *BMJ* 2020; 369:m1996

ⁱⁱⁱ Auld SC, Caridi-Scheible M, Blum JM *et al.* ICU and Ventilator mortality among critically ill adults with coronavirus disease 2019. *Critical Care Medicine* 2020;48(9):e799-e804

^{iv} Azar KMJ, Shen Z, Romanelli RJ *et al.* Disparities in outcomes among Covid-19 patients in a large healthcare system in California. *Health Affairs* 2020;39 (7)

^v Brill SE, Jarvis HC, Ozcan E *et al.* Covid-19: a retrospective cohort study with focus on the over-80s and hospital-onset disease. *BMC Medicine* **18**, 194 (2020)

^{vi} Carabello C, McCullough M, Fuery M *et al.* Covid-19 infections and outcomes in a live registry of heart failure patients across an integrated healthcare system. *MedRxiv* 2020 <https://www.medrxiv.org/content/10.1101/2020.04.27.20082016v1>

^{vii} Rajter JC, Sherman M, Fattah N *et al.* ICON (Ivermectin in COvid Nineteen) study: Use of ivermectin is associated with lower mortality in hospitalised patients with Covid-19. *MedRxiv* 2020. <https://www.medrxiv.org/content/10.1101/2020.06.06.20124461v2>

^{viii} Ebinger JE, Achamallah N, Ji H *et al.* Pre-existing traits associated with Covid-19 illness severity. *PLoS ONE* 2020;15(7):e0236240

^{ix} Ellington S, Strid P, Tong VT *et al.* Characteristics of women of reproductive age with laboratory confirmed SARS-CoV-2 infection by pregnancy status – United States, January 22-June 7, 2020. *Weekly J* June 26,2020; 69(25); 769-775

^x Garibaldi BT, Fiksel J, Muschelli J *et al.* Patient trajectories and risk factors for severe outcomes among persons hospitalised for Covid-19 in the Maryland/DC region. *MedRxiv* 2020. <https://www.medrxiv.org/content/10.1101/2020.05.24.20111864v1>

^{xi} Gold JAW, Wong KK, Szablewski CM *et al.* Characteristics and clinical outcomes of adult patients hospitalised with Covid-19 – Georgia, March 2020. *Weekly J* May 2020; 69 (18); 545-550

^{xii} Gu Y, Mack JA, Salvator M *et al.* Covid-19 outcomes, risk factors and associations by race: a comprehensive analysis using electronic health records data in Michigan Medicine. *MedRxiv* 2020 <https://www.medrxiv.org/content/10.1101/2020.06.16.20133140v1>

-
- ^{xiii} Khan A, Chatterjee A, Singh S *et al.* Comorbidities and disparities in outcomes of Covid-19 among African American and White Patients. *MedRxiv* 2020 <https://www.medrxiv.org/content/10.1101/2020.05.10.20090167v1>
- ^{xiv} Kim L, Garg S, O'Halloran A *et al.* Interim analysis of risk factors for severe outcomes among a cohort of hospitalised adults identified through the US coronavirus disease 2019 (Covid-19) associated hospitalisation surveillance network (COVID-NET). *Clinical Infectious Diseases* 2020
- ^{xv} Levy TJ, Richardson S, Coppa K *et al.* Development and validation of a survival calculator for hospitalised patients with Covid-19. *MedRxiv* 2020 <https://www.medrxiv.org/content/10.1101/2020.04.22.20075416v3>
- ^{xvi} Lo C, Nguynr LH, Drew DA *et al.* Racial and ethnic determinants of Covid-19 risk. *MedRxiv* 2020 <https://www.medrxiv.org/content/10.1101/2020.06.18.20134742v1>
- ^{xvii} Lo C, Nguynr LH, Drew DA *et al.* Racial and ethnic determinants of Covid-19 risk. *MedRxiv* 2020 <https://www.medrxiv.org/content/10.1101/2020.06.18.20134742v1>
- ^{xviii} Lusignan S, Doward J, Correa A *et al.* Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. *The Lancet Infectious Diseases* 2020; 20 (9) 1-34-1042
- ^{xix} Marcello RK, Dolle J, Grami S *et al.* Characteristics and outcomes of Covid-19 patients in New York City's Public Health System. *MedRxiv* 2020. <https://www.medrxiv.org/content/10.1101/2020.05.29.20086645v3>
- ^{xx} Valle MD, Kim-Schulze S, Huang H *et al.* An inflammatory cytokine signature predicts Covid-19 severity and survival. *Nature Medicine* 2020
- ^{xxi} Mendy A, Apewokin S, Wells AA *et al.* Factors associated with hospitalisation and disease severity in a racially and ethnically diverse population of Covid-19 patients. *MedRxiv* 2020 <https://www.medrxiv.org/content/10.1101/2020.06.25.20137323v2>
- ^{xxii} Miles A, Webb TE, Mcloughlin BC *et al.* Outcomes from Covid-19 across the range of frailty: excess mortality in fitter older people. *European Geriatric Medicine*: 2020
- ^{xxiii} Narain S, Stefanov D, Chau AS *et al.* Comparative survival analysis of immunomodulatory therapy for Covid-19 'Cytokine storm': a retrospective observational cohort study. *MedRxiv* 2020. <https://www.medrxiv.org/content/10.1101/2020.06.16.20126714v1>
- ^{xxiv} Niedzwiedz CL, O'Donnell CA, Jani BD *et al.* Ethnic and socioeconomic differences in SARS-CoV-2 infection: prospective cohort study using UK Biobank. *BMC Med* 2020, **18**, 160
- ^{xxv} Williamson EJ, Walker AJ, Bhaskaran K *et al.* Factors associated with Covid-19 related death using OpenSAFELY. *Nature* 2020 **584** 4306 -436

-
- ^{xxvi} Petrak R, Skorodin N, Hise NV *et al.* Tocilizumab as a therapeutic agent for critically ill patients infected with SARS-CoV-2. *MedRxiv* 2020. <https://www.medrxiv.org/content/10.1101/2020.06.05.20122622v1>
- ^{xxvii} Price-Haywood EG, Burton J, Fort D *et al.* Hospitalisation and mortality among black patients and white patients with Covid-19. *New England Journal of Medicine* 2020; 382:2534-2543
- ^{xxviii} Ramaswamy M, Mannam P, Comer R *et al.* Off-label real world experience using Tocilizumab for patients hospitalised with Covid-19 disease in a regional community health system: A Case-control study. *MedRxiv* <https://www.medrxiv.org/content/10.1101/2020.05.14.20099234v1>
- ^{xxix} Rentsch CT, Kidwai-Khan F, Tate JP *et al.* Covid-19 testing, hospital admission and intensive care among 2,026,227 united states veterans aged 54-75 years. *MedRxiv* <https://www.medrxiv.org/content/10.1101/2020.04.09.20059964v1>
- ^{xxx} Rosenberg ES, Dufort EM, Udo T, *et al.* Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. *JAMA*. 2020;323(24):2493–2502.
- ^{xxxi} Sapey E, Gallier S, Mainey C *et al.* Ethnicity and risk of death in patients hospitalised for Covid-19 infection: an observational cohort study in an urban catchment area. *MedRxiv* 2020: <https://www.medrxiv.org/content/10.1101/2020.05.05.20092296v2>
- ^{xxxii} Somers EC, Eschenauer GA, Troost JP *et al.* Tocilizumab for treatment of mechanically ventilated patients with Covid-19. *Clinical Infectious Diseases* 2020 ciaa954
- ^{xxxiii} Vahidy FS, Nicolas JC, Meeks JR *et al.* Racial and ethnic disparities in SARS-CoV-2 pandemic: analysis of COVID-19 observational registry for a diverse US metropolitan population. *BMJ Open* 2020; **10**Le039839
- ^{xxxiv} Velu P, Craney A, Ruggiero P *et al.* Rapid implementation of SARS-CoV-2 emergency use authorisation RT-PCR testing and experience at an academic medical institution *MedRxiv* 2020; <https://www.medrxiv.org/content/10.1101/2020.06.05.20109637v1>
- ^{xxxv} Wang A, Zhong X, Hurd Y. Comorbidity and Sociodemographic determinants in Covid-19 mortality in an US Urban Healthcare System. *MedRxiv* 2020. <https://www.medrxiv.org/content/10.1101/2020.06.11.20128926v1>
- ^{xxxvi} Wang Z, Zheutlin AB, Kao Y *et al.* Analysis of hospitalised Covid-19 patients in the Mount Sinai Health System using electronic medical records (EMR) reveals important prognostic factors for improved clinical outcomes. *MedRxiv* 2020. <https://www.medrxiv.org/content/10.1101/2020.04.28.20075788v1>

Table 2. Data syntheses for risk of SARS-CoV-2 infection by ethnic group

	Studies	Pooled prevalence (95% CI)	I ²	Studies	Pooled OR (95% CI)	I ²	Studies	Pooled RR (95% CI)	I ²
White	13	0.13 (0.12, 0.13)	99.9		Reference			Reference	
Asian	10	0.18 (0.15, 0.20)	99.6	10	1.55 (1.13, 2.13)	96.3	4	1.35 (1.15, 1.59)	0
Black	13	0.29 (0.22, 0.36)	99.9	12	2.50 (1.88, 3.32)	96.6	6	2.06 (1.59, 2.67)	86.7
Hispanic	7	0.21 (0.09, 0.33)	99.97	7	2.44 (1.90, 3.15)	94.8	3	1.77 (1.39, 2.25)	0
Mixed	1	0.33 (0.16, 0.56)	-	1	0.96 (0.36, 2.58)	-	0	-	-
Native American	1	0.02 (0.01, 0.07)	-	1	0.31 (0.08, 1.26)	-	0	-	-

Table 3. Data syntheses for risk of ICU admission amongst different ethnic groups

	Studies	Pooled prevalence (95% CI)	I ²	Studies	Pooled unadjusted OR (95% CI)	I ²	Studies	Pooled adjusted RR (95% CI)	I ²
(1) Studies including both hospitalised and inpatient/outpatient populations									
White	10	0.15 (0.10, 0.20)	98.1		Reference			Reference	
Asian	5	0.16 (0.09, 0.24)	86.5	5	1.35 (0.69, 2.64)	85.0	0	-	-
Black	11	0.24 (0.19, 0.28)	94.9	10	1.73 (1.17, 2.56)	92.7	4	1.61 (1.02, 2.55)	92.1
Hispanic	6	0.17 (0.11, 0.23)	93.0	6	0.88 (0.71, 1.10)	41.3	2	1.62 (0.53, 4.97)	88.5
Native American	0	-	-	1	1.65 (0.08, 34.79)	-	0	-	-
(2) Studies including hospitalised populations only or reporting a subgroup analysis for hospitalised patients only									
White	10	0.28 (0.21, 0.36)	97.9		Reference			Reference	
Asian	5	0.27 (0.17, 0.36)	80.4	5	1.68 (0.95, 2.99)	76.2	0	-	-
Black	11	0.35 (0.25, 0.44)	97.8	10	1.29 (1.06, 1.58)	61.9	1	1.01 (0.89, 1.15)	-
Hispanic	6	0.31 (0.19, 0.42)	96.1	6	0.97 (0.71, 1.33)	66.5	1	0.96 (0.76, 1.21)	-

Table 4. Data syntheses for risk of mortality by different ethnic groups

	Studies	Pooled prevalence (95% CI)	I ²	Studies	Pooled unadjusted OR (95% CI)	I ²	Studies	Pooled adjusted HR/RR (95% CI)	I ²
(1) Studies including COVID positive/suspected patients only									
White	18	0.20 (0.15, 0.25)	99.2		Reference			Reference	
Asian	10	0.21 (0.13, 0.29)	95.85	10	0.82 (0.71, 0.94)	17.0	2	1.27 (0.75, 2.15)	89.6
Black	19	0.16 (0.13, 0.20)	97.5	18	0.92 (0.73, 1.17)	88.4	11	1.06 (0.90, 1.26)	44.0
Hispanic	9	0.11 (0.06, 0.17)	98.8	9	0.51 (0.37, 0.71)	66.1	4	1.01 (0.71, 1.45)	30.9
Mixed	1	0.33 (0.16, 0.56)	-	1	1.21 (0.45, 3.25)	-	1	1.94 (0.86, 4.37)	-
(2) Studies including COVID positive/suspected patients plus studies of general populations									
White	-	-	-		Reference			Reference	
Asian	-	-	-	11	0.87 (0.73, 1.04)	59.3	4	1.46 (1.12, 1.92)	80.1
Black	-	-	-	19	0.95 (0.75, 1.20)	90.2	13	1.15 (0.94, 1.40)	69.7
Hispanic	-	-	-	9	0.51 (0.37, 0.71)	66.1	4	1.01 (0.71, 1.45)	30.9
Mixed	-	-	-	2	0.75 (0.51, 1.10)	11.5	3	1.47 (1.01, 2.12)	28.8
(3) Excluding studies from (1) which did not include hospitalised patients in outcome									
White	16	0.19 (0.15, 0.24)	98.3		Reference			Reference	
Asian	9	0.20 (0.11, 0.29)	94.75	9	0.79 (0.66, 0.96)	19.3	2	1.27 (0.75, 2.15)	89.6
Black	17	0.16 (0.12, 0.20)	97.3	16	0.97 (0.73, 1.30)	87.4	9	1.07 (0.81, 1.33)	55.2
Hispanic	8	0.12 (0.06, 0.18)	98.9	8	0.55 (0.39, 0.78)	64.4	3	0.67 (0.26, 1.70)	36.4
Mixed	1	0.33 (0.16, 0.56)	-	1	1.21 (0.45, 3.25)	-	1	1.94 (0.86, 4.37)	-

(4) Excluding studies from (1) where the denominator was not of hospitalised patients

White	13	0.26 (0.22, 0.30)	91.7		Reference			Reference	
Asian	8	0.26 (0.24, 0.28)	0	8	0.80 (0.67, 0.95)	26.0	2	1.27 (0.70, 2.15)	89.6
Black	14	0.20 (0.17, 0.23)	85.7	13	0.74 (0.62, 0.89)	65.8	8	0.98 (0.87, 1.11)	0
Hispanic	8	0.13 (0.05, 0.21)	96.9	8	0.49 (0.33, 0.70)	67.4	3	1.00 (0.66, 1.52)	51.1
Mixed	1	0.33 (0.16, 0.56)	-	1	1.21 (0.45, 3.25)	-	1	1.94 (0.86, 4.37)	-

Figure 1: PRISMA Flow Diagram.

